Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.38 |
| ▸ | CASP4 | P49662 | 1/20 | 0.38 |
| ▸ | CASP5 | P51878 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | CHKA | P35790 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5781067 | 0.98 | ALDH1A1 (0.43) | ALDH1A1MAPTKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL4718969 | 0.98 | ALDH1A1 (0.43) | ALDH1A1MAPTKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL11753233 | 0.98 | ALDH1A1 (0.43) | ALDH1A1MAPTKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL28956840 | 0.95 | — | — | |
| Pyrazole SCHEMBL8016222 | 0.86 | HPGD (0.40) | ALDH1A1MAPTKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL18592849 | 0.83 | ELOVL1 (0.40) | ALDH1A1MAPTKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL1559213 | 0.83 | PLD1 (0.48) | ALDH1A1KDM4EHPGDHSD17B10CYP1A2 | |
| SCHEMBL18592825 | 0.82 | L3MBTL3 (0.53) | — | |
| SCHEMBL4939322 | 0.81 | HTT (0.42) | ALDH1A1MAPTKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL18592791 | 0.81 | HTR3A (0.46) | ALDH1A1KDM4ECYP1A2HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2892892-B1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-31 | — | — | EP | claimed |
| EP-2892892-A1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR!THE TREATMENT OF CANCER | Janssen Pharmaceutica N.V. (BE) | 2015-07-15 | — | — | EP | claimed |
| WO-2014039769-A1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR|THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-13 | — | — | WO | claimed |
| CN-85103468-A | Prepare the method for new compound and new purposes thereof | — | 1986-09-10 | — | — | CN | claimed |
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4721737-A1 | USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES | Scinnohub Pharmaceutical Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-20250367222-A1 | TREATMENTS FOR CANCERS DRIVEN BY DNAJB1-PRKACA GENE FUSIONS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250145635-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| EP-4455136-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | Scinnohub Pharmaceutical Co., Ltd. (CN) | 2024-10-30 | — | — | EP | disclosed |
| WO-2024184520-A1 | BIARYLAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-09-12 | — | — | WO | disclosed |
| WO-2024088343-A1 | ARYL HETEROCYCLIC KV1.3 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海深势唯思科技有限责任公司 | 2024-05-02 | — | — | WO | disclosed |
| WO-2023116774-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | 赛诺哈勃药业（成都）有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2014039769-A1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR|THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-13 | — | — | WO | disclosed |
| CN-102753554-A | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC | 2012-10-24 | — | — | CN | disclosed |
| US-6559174-B2 | For therapy of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis | MERCK & CO., INC. | 2003-05-06 | — | — | US | disclosed |
| US-20020193399-A1 | N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors | MERCK & CO., INC. | 2002-12-19 | — | — | US | disclosed |
| CN-1252806-A | Dolastatin-15 derivatives having carbonyl and heterocyclic functional groups at the C-terminus | BASF AG (DE) | 2000-05-10 | — | — | CN | disclosed |
| EP-0981539-A1 | DOLASTATIN 15 DERIVATIVES WITH CARBONYL AND HETEROCYCLIC FUNCTIONALITIES AT THE C-TERMINUS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-01 | — | — | EP | disclosed |
| US-5965537-A | ANTICANCER AGENTS; WATER SOLUBILITY | BASF AKTIENGESELLSCHAFT (DE) | 1999-10-12 | — | — | US | disclosed |
| WO-1998040400-A1 | DOLASTATIN 15 DERIVATIVES WITH CARBONYL AND HETEROCYCLIC FUNCTIONALITIES AT THE C-TERMINUS | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | KIF2C, KIF5B, KIF5C | ALDH1A1 2556/4885MAPT 520/4885KDM4E 3337/4885 |
| US-20250145635-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | BCL9, USP9X, BCL9L | ALDH1A1 2611/4885MAPT 3783/4885KDM4E 1211/4885 |
| US-20020193399-A1 | N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors | VCAM1, CD4, ITGA4 | ALDH1A1 195/4885MAPT 1264/4885KDM4E 763/4885 |
| US-20250367222-A1 | TREATMENTS FOR CANCERS DRIVEN BY DNAJB1-PRKACA GENE FUSIONS | CDK9, CDC73, CDK4 | ALDH1A1 3286/4885MAPT 3412/4885KDM4E 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.